Novo Nordisk's chief financial officer said: Currently, Wegovy oral tablets are mainly purchased by patients at their own expense. Affected by market dynamics, prices are likely to be adjusted in the future.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.